Nektar Therapeutics

DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2023 Financial Results

Retrieved on: 
Tuesday, March 19, 2024
Health, FDA, Clinical Trials, Pharmaceutical, Cardiology, Biotechnology, Epilepsy, TPA, AIS, Patient, Tissue plasminogen activator, Stroke, G&A, Investment, Therapy, Pharmacovigilance, Nektar Therapeutics, Research, KLK1, Biostatistics, NKTR, Trial of the century, DSM-IV codes, NIHSS, Amgen, Data management, Pharmacy, Food, Cubist Pharmaceuticals, Neurology, Rankine scale, Shanghai Pharmaceuticals, DMAC, Acquisition, University, Yale University, Psychiatry, MRS, ASTN, Takeda, Patent, Bangladesh Technical Education Board, Probability, Pharmaceutical industry

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, today provided a business update and financial results for the year ended December 31, 2023.

Key Points: 
  • DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, today provided a business update and financial results for the year ended December 31, 2023.
  • Management will host a conference call Wednesday, March 20, 2024, at 8:00 AM Eastern Time / 7:00 AM Central Time to discuss its business update and full year 2023 financial results.
  • Other income, net, was $1.9 million for the year ended December 31, 2023 compared to $0.4 million for 2022.
  • DiaMedica Management will host a conference call and webcast to discuss its business update and full year quarter 2023 financial results on Wednesday, March 20, 2024, at 8:00 AM Eastern Time / 7:00 AM Central Time:

Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference

Retrieved on: 
Friday, March 22, 2024
SAN, Conference, Q&A, NKTR, Nektar Therapeutics, Therapy, Nektar

SAN FRANCISCO, March 22, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) management is scheduled to present at the upcoming H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference on Thursday, March 28, 2024 at 1:30 p.m. Eastern Time / 10:30 a.m. Pacific Time.

Key Points: 
  • SAN FRANCISCO, March 22, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) management is scheduled to present at the upcoming H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference on Thursday, March 28, 2024 at 1:30 p.m. Eastern Time / 10:30 a.m. Pacific Time.
  • The presentation and Q&A session will be accessible via a webcast through a link posted on the Investor Events section of the Nektar website: https://ir.nektar.com/events-and-presentations/events .
  • This webcast will be available for replay until April 28, 2024.

Y-mAbs Appoints Oncology Executive Mary Tagliaferri, M.D. to its Board of Directors

Retrieved on: 
Monday, March 4, 2024
Cornell University, Therapy, Acquisition, Nektar, Senior, Woman of the Year, American City Business Journals, Immunotherapy, Disassembler, Assembly, Nektar Therapeutics, Bristol Myers Squibb, Entrepreneurship, Radioimmunotherapy, University, Self-assembly, Woman, Cancer, Medical device

to the Company’s Board of Directors, effective February 29, 2024.

Key Points: 
  • to the Company’s Board of Directors, effective February 29, 2024.
  • Dr. Tagliaferri brings nearly 30 years of biopharmaceutical industry experience and oncology therapeutic development expertise to the Y-mAbs Board of Directors.
  • “We are thrilled to welcome Mary to our Board of Directors during such an exciting time for Y-mAbs,” said Michael Rossi, President and Chief Executive Officer.
  • Nektar is a clinical-stage, research-based drug discovery biopharmaceutical company focuses on discovering and developing innovative medicines in the field of immunotherapy.

Nektar Management to Present at the TD Cowen 44th Annual Health Care Conference

Retrieved on: 
Tuesday, February 27, 2024
SAN, Nektar, Q&A, Therapy, NKTR, Nektar Therapeutics, Conference

SAN FRANCISCO, Feb. 27, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) management is scheduled to present at the upcoming TD Cowen 44th Annual Health Care Conference in Boston on Tuesday, March 5, 2024 at 2:10 p.m. Eastern Time.

Key Points: 
  • SAN FRANCISCO, Feb. 27, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) management is scheduled to present at the upcoming TD Cowen 44th Annual Health Care Conference in Boston on Tuesday, March 5, 2024 at 2:10 p.m. Eastern Time.
  • The presentation and Q&A session will be accessible via a webcast through a link posted on the Investor Events section of the Nektar website: https://ir.nektar.com/events-and-presentations/events .
  • This webcast will be available for replay until April 5, 2024.

Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2023 on Monday, March 4, 2024, After Close of U.S.-Based Financial Markets

Retrieved on: 
Monday, February 26, 2024
SAN, Home page, Nektar, Therapy, NKTR, PIN, Nektar Therapeutics

SAN FRANCISCO, Feb. 26, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2023 on Monday, March 4, 2024, after the close of U.S.-based financial markets.

Key Points: 
  • SAN FRANCISCO, Feb. 26, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2023 on Monday, March 4, 2024, after the close of U.S.-based financial markets.
  • Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time.
  • The web broadcast of the conference call will be available for replay through April 4, 2024.
  • All registrants will receive dial-in information and a PIN allowing them to access the live call.

DiaMedica Therapeutics Appoints Dr. Lorianne Masuoka as Chief Medical Officer

Retrieved on: 
Monday, January 22, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Cardiology, Psychiatry, Cubist Pharmaceuticals, Amgen, Patient, Therapy, Employment, Neurology, Biostatistics, Data management, DMAC, Pharmacovigilance, Stroke, University, NKTR, Yale University, Acquisition, Epilepsy, Nektar Therapeutics, DSM-IV codes, Pharmaceutical industry

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, announced today the appointment of Lorianne Masuoka, M.D.

Key Points: 
  • DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, announced today the appointment of Lorianne Masuoka, M.D.
  • as Chief Medical Officer.
  • “We are delighted to have Lorianne join our executive leadership team,” said Rick Pauls, DiaMedica’s President and Chief Executive Officer.
  • Dr. Masuoka received her medical degree from the University of California, Davis, where she also completed her residency in neurology.

Chimerix Appoints Lisa Decker to Board of Directors

Retrieved on: 
Friday, December 29, 2023
Associate, IGM, College, Therapy, University, Business development, Holy Cross, Doctor of Philosophy, FAAN, Technology management, RN, Nektar Therapeutics, Patient, Priscilla Chan, Management

DURHAM, N.C., Dec. 29, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced Lisa Decker, Chief Business Officer at IGM Biosciences, has been appointed to Chimerix's Board of Directors.

Key Points: 
  • DURHAM, N.C., Dec. 29, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced Lisa Decker, Chief Business Officer at IGM Biosciences, has been appointed to Chimerix's Board of Directors.
  • Ms. Decker replaces Catherine Gilliss PhD, RN, FAAN, who is simultaneously retiring from the Chimerix Board after nearly 10 years of service.
  • “We are delighted to welcome Lisa to the Chimerix Board of Directors.
  • “We also thank Catherine for her valuable insight and judgement to the Chimerix Board over her tenure and for the impact she has had on the company during that time.

Inspire Medical Systems, Inc. Announces Appointment of Seasoned Medical Device Executive Myriam J. Curet, M.D. to its Board of Directors

Retrieved on: 
Thursday, December 28, 2023
Obstructive sleep apnea, Physician, University, Curette, Therapy, Stanford University, OSA, Nektar Therapeutics, Patient, Arrhythmia, Harvard Medical School, Intuitive Surgical

“We are excited to add Dr. Curet, a practicing, board-certified minimally invasive general surgeon with extensive business and executive leadership experience in the medical device industry to our Board of Directors,” said Tim Herbert, President and Chief Executive Officer of Inspire Medical Systems.

Key Points: 
  • “We are excited to add Dr. Curet, a practicing, board-certified minimally invasive general surgeon with extensive business and executive leadership experience in the medical device industry to our Board of Directors,” said Tim Herbert, President and Chief Executive Officer of Inspire Medical Systems.
  • “Dr.
  • Dr. Curet is also Professor of Surgery at Stanford University and previously held a faculty role at the University of New Mexico.
  • Dr. Curet received her Doctor of Medicine degree from Harvard Medical School, completed her residency in general at the University of Chicago and completed her fellowship in surgical endoscopy at the University of New Mexico.

Nucleome Therapeutics appoints Dr Stephen Harrison as Chief Scientific Officer

Retrieved on: 
Monday, November 13, 2023
Natural science, University, Genetics, Research, Senior, Therapy, Nektar Therapeutics, Biotechnology, Pain management, Genomics, Chiron Corporation, Molecular biology, Genome, Nektar, Drug discovery, San Francisco Bay Area, Doctor of Philosophy, Amgen, Pharmaceutical industry, Management

Oxford, UK, 13 November 2023 – Nucleome Therapeutics (‘Nucleome’ or ‘the Company’), a biotechnology company decoding the dark matter of the human genome for translational medicine, today announces the appointment of Dr Stephen Harrison as Chief Scientific Officer, effective immediately.

Key Points: 
  • Oxford, UK, 13 November 2023 – Nucleome Therapeutics (‘Nucleome’ or ‘the Company’), a biotechnology company decoding the dark matter of the human genome for translational medicine, today announces the appointment of Dr Stephen Harrison as Chief Scientific Officer, effective immediately.
  • Prior to joining Nucleome, Dr Harrison held executive leadership positions at several biotechnology companies in the San Francisco Bay Area.
  • Most recently, he served as Chief Scientific Officer at Engine Biosciences, building and leading a team focused on functional genomics and machine learning-led target and drug discovery.
  • Dr Danuta Jeziorska, Chief Executive Officer and Founder of Nucleome, commented: “Steve has an outstanding track record in accelerated drug discovery and development across multiple therapeutic areas and innovative technologies.

Nektar to Announce Financial Results for the Third Quarter 2023 on Tuesday, November 7, 2023, After Close of U.S.-Based Financial Markets

Retrieved on: 
Tuesday, October 31, 2023
Nektar, Home page, Nektar Therapeutics, Therapy, NKTR, PIN, SAN, Cryptocurrency

SAN FRANCISCO, Oct. 31, 2023 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter 2023 on Tuesday, November 7, 2023, after the close of U.S.-based financial markets.

Key Points: 
  • SAN FRANCISCO, Oct. 31, 2023 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter 2023 on Tuesday, November 7, 2023, after the close of U.S.-based financial markets.
  • Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time.
  • The web broadcast of the conference call will be available for replay through December 8, 2023.
  • All registrants will receive dial-in information and a PIN allowing them to access the live call.